產(chǎn)品搜索
相關(guān)文章
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進(jìn)展
- ATCC細(xì)胞株的特殊性質(zhì)或標(biāo)志必須在整個(gè)培養(yǎng)期間始終存在
- 【連載-企業(yè)參考品】 前列腺癌的診斷參考品的選擇
- KIR3DL3/HHLA2細(xì)胞篩選模型
- 重磅!科學(xué)家成功利用免疫細(xì)胞運(yùn)輸抗癌藥物至腫瘤靶點(diǎn)
- CYP1A1基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- ANG TIE2:重塑千億血管靶向治療市場,“血管-免疫”協(xié)同治療革命
- 黃金賽道——CDH17靶點(diǎn)
- 免疫治療的下一個(gè)靶標(biāo):腫瘤相關(guān)巨噬細(xì)胞?
- IHC第三方質(zhì)控品——病理質(zhì)控基石,精準(zhǔn)診斷起點(diǎn)
聯(lián)系我們
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73302BCR-ABL1 E459K/BaF3

- 詳細(xì)內(nèi)容
CBP73302 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [E459K]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1.WB of BCR-ABL1 [E459K]/BaF3 | |
2.Sanger of BCR-ABL1 [E459K]/BaF3 Figure 2. BCR-ABL1 [E459K]/BaF3 E549K
Figure 3. BCR-ABL1 [E459K]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 E459K Cells (C8). | |